180 related articles for article (PubMed ID: 36860731)
1. Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis.
Cui S; Zhang M; Bai S; Bi Y; Cong S; Jin S; Li S; He H; Zhang J
Oxid Med Cell Longev; 2023; 2023():1847700. PubMed ID: 36860731
[TBL] [Abstract][Full Text] [Related]
2. Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of Ovarian Cancer.
Wang K; He H; Feng X
J Immunol Res; 2022; 2022():2359349. PubMed ID: 35800989
[TBL] [Abstract][Full Text] [Related]
3. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.
Cao L; Liu M; Ma X; Rong P; Zhang J; Wang W
Curr Med Chem; 2024; 31(17):2414-2430. PubMed ID: 37936457
[TBL] [Abstract][Full Text] [Related]
5. Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis.
Dai Z; Peng X; Guo Y; Shen X; Ding W; Fu J; Liang Z; Song J
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2393-2416. PubMed ID: 35731273
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtypes based on metabolic genes are potential biomarkers for predicting prognosis and immune responses of clear cell renal cell carcinoma.
Wang Y; Ji H; Zhu B; Xing Q; Xie H
Eur J Immunol; 2023 Jan; 53(1):e2250105. PubMed ID: 36367018
[TBL] [Abstract][Full Text] [Related]
7. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract][Full Text] [Related]
8. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.
Huo J; Cai J; Wu L
Cancer Med; 2023 Jan; 12(1):898-912. PubMed ID: 35651292
[TBL] [Abstract][Full Text] [Related]
10. Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma.
Liu X; Sun B; Yao Y; Lai L; Wang X; Xiong J; Zhang X; Jiang J
Front Immunol; 2022; 13():996308. PubMed ID: 36275743
[TBL] [Abstract][Full Text] [Related]
11. Identification of subclusters and prognostic genes based on glycolysis/gluconeogenesis in hepatocellular carcinoma.
Chen D; Aierken A; Li H; Chen R; Ren L; Wang K
Front Immunol; 2023; 14():1232390. PubMed ID: 37881434
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
14. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
15. A Mitophagy-Related Gene Signature for Subtype Identification and Prognosis Prediction of Hepatocellular Carcinoma.
Liu C; Wu Z; Wang L; Yang Q; Huang J; Huang J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292980
[TBL] [Abstract][Full Text] [Related]
16. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
17. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
19. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.
Bai J; Tang R; Zhou K; Chang J; Wang H; Zhang Q; Shi J; Sun C
BMC Med Genomics; 2022 Oct; 15(1):222. PubMed ID: 36284275
[TBL] [Abstract][Full Text] [Related]
20. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions.
Zheng Q; Yang Q; Zhou J; Gu X; Zhou H; Dong X; Zhu H; Chen Z
Cancer Cell Int; 2021 Jun; 21(1):330. PubMed ID: 34193146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
